Merck Serono, the biopharmaceutical division of Merck, has appointed Steven Hildemann as Global Chief Medical Officer (CMO) and Head of Global Medical and Safety.
Dr Hildemann will be based in Darmstadt, Germany and report to Annalisa Jenkins, Global Head of Research & Development of Merck Serono. He will be responsible for Global Medical Affairs, Global Drug Safety and External Scientific Affairs for Merck Serono. He will also become a member of the R&D Executive Leadership Team.
In addition, Hildemann will be responsible for medical governance, chairing the Medical Safety and Ethics Board and the Bioethics Committee. Prior to joining Merck Serono, Hildemann was Associate Vice President, Global Clinical Trial Operations Europe, MSD (in the US: Merck & Co).
Hildemann joined the pharmaceutical industry in 1998 as the country medical director cardiovascular for Searle in Germany. After the merger with Pharmacia, he progressed to positions of increasing responsibility and in 2002 moved to New Jersey/US as the Senior Global Medical Director Cardiovascular for Pharmacia, and later Pfizer.
In 2004, Hildemann joined Schering-Plough (SP) as the country medical director in Germany. In 2006, he led the Global Clinical Harmonisation at Schering-Plough and global integration activities for MSD Research-Laboratories during the merger of SP and MSD.
Hildemann succeeds Dr Florian Bieber in the CMO role at Merck Serono. Bieber left the company in December 2013 to pursue other opportunities.
